ABSTRACT
Introduction The vaccine against SARS-CoV-2 provides humoral immunity to fight COVID-19; however, the acquired immunity gradually declines. Booster vaccination restores reduced humoral immunity; however, its effect on newly emerging variants, such as the Omicron variant, is a concern. As the waves of COVID-19 cases and vaccine programs differ between countries, it is necessary to know the domestic effect of the booster.
Methods Serum samples were obtained from healthcare workers (20-69 years old) in the Pfizer BNT162b2 vaccine program at the Toyama University Hospital 6 months after the second dose (6mA2D, n = 648) and 2 weeks after the third dose (2wA3D, n = 565). The anti-SARS-CoV-2 antibody level was measured, and neutralization against the wild-type and variants (Delta and Omicron) was evaluated using pseudotyped viruses. Data on booster-related events were collected using questionnaires.
Results The median anti-SARS-CoV-2 antibody was >30.9-fold elevated after the booster (6mA2D, 710.0 U/mL [interquartile range (IQR): 443.0–1068.0 U/mL]; 2wA3D, 21927 U/mL [IQR: 15321.0–>25000.0 U/mL]). Median neutralizing activity using 100-fold sera against wild-type-, Delta-, and Omicron-derived variants was elevated from 84.6%, 36.2%, and 31.2% at 6mA2D to >99.9%, 99.1%, and 94.6% at 2wA3D, respectively. The anti-SARS-CoV-2 antibody levels were significantly elevated in individuals with fever ≥37.5 °C, general fatigue, and myalgia, local swelling, and local hardness.
Conclusion The booster effect, especially against the Omicron variant, was observed in the Japanese population. These findings contribute to the precise understanding of the efficacy and side effects of the booster and the promotion of vaccine campaigns.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Emerging and Re-emerging Infectious Diseases from the AMED (grant number JP20he0622035), the Research Funding Grant from the president of the University of Toyama, Morinomiyako Medical Research Foundation, and Kurozumi Medical Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of Toyama gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authorship statement: Conceptualization: YMo; Methodology: HK, YMo, and HT; Validation: HK and YMo; Formal Analysis: HK and YMo; Investigation: HK, YMo, MK, YuMu (neutralizing assay), and HN (commercial antibody test); Resources: HT, TS, EI, YS (generating pseudotyped viruses), CO, YMa (generating plasmids), HK, MK, YMu, AU, YMi, YF, and KN (serum sample collection); Data Curation: HK and YMo; Writing–Original Draft Preparation: HK, YMo and HT; Writing–Review and Editing: HK, YMo, and HT; Visualization: HK, YMo; Supervision: YMa, HN, and YYa; Project Administration: YMo and YYa; Funding acquisition: HK, YMo, HT, HN, and YYa
All authors meet the ICMJE authorship criteria.1
↵1 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, COVID-19: coronavirus disease 2019, VOC: Variant of Concern, CRNT: chemiluminescence reduction neutralization test, htCRNT: high throughput chemiluminescence reduction neutralization test, RBD: receptor-binding domain, 6mA2D: 6 months after the second dose, 2wA3D: 2 weeks after the third dose, DMEM: Dulbecco’s modified Eagle’s medium, NT50: half-maximal neutralizing titer, IQR: interquartile range, VSVs: vesicular stomatitis viruses
Data Availability
All data produced in the present work are contained in the manuscript
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- COVID-19
- coronavirus disease 2019
- VOC
- Variant of Concern
- CRNT
- chemiluminescence reduction neutralization test
- htCRNT
- high throughput chemiluminescence reduction neutralization test
- RBD
- receptor-binding domain
- 6mA2D
- 6 months after the second dose
- 2wA3D
- 2 weeks after the third dose
- DMEM
- Dulbecco’s modified Eagle’s medium
- NT50
- half-maximal neutralizing titer
- IQR
- interquartile range
- VSVs
- vesicular stomatitis viruses